Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts
Li Y, Saba L, Scheinman R, Banda N, Holers M, Monte A, Dylla L, Moghimi S, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano 2024, 18: 28649-28658. PMID: 39395006, PMCID: PMC11651220, DOI: 10.1021/acsnano.4c05087.Peer-Reviewed Original ResearchConceptsPegylated liposomal doxorubicinComplement activationPredictive valuePlasma concentrationsC-reactive protein levelsAnti-PEG IgGTriggers proinflammatory responsesAnti-PEG IgMEfficacy of nanomedicinesPoor predictive valueAnti-PEG antibodiesLiposomal doxorubicinIron oxide nanowormsHealthy donorsHigher complement activationAcute infectionInflammatory disease conditionsChronic inflammationProinflammatory responseSystemic administrationComplement cascadeComplement factorsComplement responseIgMProtein levelsOptimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi S, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics 2024, 21: 3053-3060. PMID: 38743264, DOI: 10.1021/acs.molpharmaceut.4c00278.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayLiposomal doxorubicinHealthy donorsPatients treated with pegylated liposomal doxorubicinEnzyme-linked immunosorbent assay signalCancer patientsAnti-PEG IgGPegylated liposomal doxorubicinImmunosorbent assayOptimized ELISAEnzyme-linked immunosorbent assay protocolsAnti-PEG antibodiesChemotherapy cyclesBetween-assay variabilityPEGylated liposomesCutoff valueAccelerated clearanceTreatment cyclesDrug delivery systemsAntibody titersComplement activationInfused drugAnti-PEGOptimized assayPatientsValidation of dot blot immunoassay for measurement of complement opsonization of nanoparticles
Li Y, Monte A, Dylla L, Moghimi S, Simberg D. Validation of dot blot immunoassay for measurement of complement opsonization of nanoparticles. Journal Of Immunological Methods 2024, 528: 113668. PMID: 38574804, PMCID: PMC11023749, DOI: 10.1016/j.jim.2024.113668.Peer-Reviewed Original ResearchConceptsDeposition of C3Complement activation markersSurface C3 depositionMembrane attack complex C5b-9Activation markersDot blot immunoassayC3 depositionAnaphylatoxins C3aImmune responseNanomedicine researchC5b-9Complement attackComplement activationBlot immunoassayFluid phase markerMarkersPhase markersImmunoassaySurface resultsPathway specificityAssembly of C3 convertaseComplementNanoparticles
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply